会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • GROUP OF ESTERASES FOR THE ENANTIOSELECTIVE PRODUCTION OF FINE AND SPECIALITY CHEMICALS
    • US20090311745A1
    • 2009-12-17
    • US12300275
    • 2007-05-03
    • Klaus LiebetonJürgen EckUwe BornscheuerDominique BöttcherPeter LangerEsen Bellur
    • Klaus LiebetonJürgen EckUwe BornscheuerDominique BöttcherPeter LangerEsen Bellur
    • C12P21/00C12P7/62C12P7/40C12P7/02C12N15/00C12N15/74C12N9/18C12N1/21C12N15/63C07K16/40C07H21/00
    • C12N9/18
    • The present invention relates to a polynucleotide encoding an enzyme having carboxylesterase [E.C. 3.1.1.1] activity, wherein the coding sequence is selected from the group consisting of (a) a polynucleotide encoding an amino acid sequence as depicted in any one of SEQ ID NOs: 2, 4, 6, 8, 10 and 12; (b) a polynucleotide having or comprising a nucleotide sequence encoding an enzyme, wherein the nucleic acid sequence is as shown in any one of SEQ ID NOs: 1, 3, 5, 7, 9 and 11; (c) a polynucleotide having or comprising a nucleotide sequence encoding a fragment or derivative of an enzyme encoded by a polynucleotide of (a) or (b), wherein in said derivative one or more amino acid residues are conservatively substituted compared to the amino acid sequence of (a); (d) a polynucleotide encoding an enzyme having carboxylesterase activity which polynucleotide is at least 66% identical to a polynucleotide encoding an enzyme as shown in one of SEQ ID NOs: 2, 4, 6, 8, 10 and 12; (e) a polynucleotide having or comprising a nucleotide sequence the complementary strand of which hybridizes to a polynucleotide as defined in any one of (a) to (d); and (f) a polynucleotide having or comprising a nucleotide sequence being degenerate to the nucleotide sequence of the polynucleotide of (d) or (e); or the complementary strand of such a polynucleotide of (a) to (f) or fragments thereof useful as specific probes or primers. The present invention also relates to a host genetically engineered with the polynucleotide of the present invention or the vector of the present invention. The present invention also relates to a process for producing a polypeptide having carboxylesterase [E.C. 3.1.1.1] activity, comprising culturing the host of the present invention and recovering the polypeptide produced by said host. Moreover, The present invention also relates to a process for producing bacteria or eukaryotic cells capable of expressing a polypeptide having carboxylesterase [E.C. 3.1.1.1] activity, the process comprising genetically engineering bacteria or eukaryotic cells with the vector of the present invention. Finally, the present invention relates to (poly)peptides, antibodies, compositions and various methods for the production of optically active compounds.
    • 6. 发明授权
    • Recombinant mistletoe lectin (rML)
    • 重组槲寄生凝集素(rML)
    • US06271368B1
    • 2001-08-07
    • US08776059
    • 1997-06-19
    • Hans LentzenJürgen EckAxel BaurHolger Zinke
    • Hans LentzenJürgen EckAxel BaurHolger Zinke
    • C12N121
    • C07K14/42A61K38/00A61K47/6819C07K2319/00
    • The invention relates to nucleic acid molecules encoding preproproteins having after maturation the biological activity of the mistletoe lectin dimer, to vectors comprising these nucleic acid molecules, to hosts transformed with said vectors and to polypeptides and/or polypeptide dimers which are encoded by these nucleic acid molecules. The polypeptides and/or polypeptide dimers of the invention are widely therapeutically applicable. Thus, the present invention further relates to immunotoxins as well as to pharmaceutical compositions that contain the polypeptides and/or the polypeptide dimers of the invention. Additionally, the invention relates to diagnostic compositions comprising the nucleic acid molecules of the invention, the polypeptides and/or the polypeptide dimers of the invention and/or primers which hybridize specifically to the nucleic acid molecules of the invention. Finally, the invention relates to plant protective agents comprising the polypeptides of the invention and/or the polypeptide dimers of the invention.
    • 本发明涉及将成熟后槲皮素凝集素二聚体的生物活性的前蛋白质,包含这些核酸分子的载体转染到用所述载体转化的宿主的核酸分子和由这些核酸编码的多肽和/或多肽二聚体 分子。 本发明的多肽和/或多肽二聚体在广泛的治疗上是适用的。 因此,本发明还涉及免疫毒素以及含有本发明的多肽和/或多肽二聚体的药物组合物。 另外,本发明涉及包含本发明的核酸分子,本发明的多肽和/或多肽二聚体的诊断组合物和/或与本发明的核酸分子特异性杂交的引物。 最后,本发明涉及包含本发明的多肽和/或本发明的多肽二聚体的植物保护剂。
    • 7. 发明授权
    • Surface active proteins as excipients in solid pharmaceutical formulations
    • 表面活性蛋白作为固体药物制剂中的赋形剂
    • US08226967B2
    • 2012-07-24
    • US13130128
    • 2009-11-13
    • Andreas ButheAndreas HafnerFranz KaufmannEsther GaborGuido MeurerJürgen EckGordon Bradley
    • Andreas ButheAndreas HafnerFranz KaufmannEsther GaborGuido MeurerJürgen EckGordon Bradley
    • A01N25/34C07K1/00
    • A61K9/4891A61K9/0065A61K9/2063A61K9/2095A61K9/2873C07K14/37
    • The invention relates to a use of surface active hydrophobins for applications in pharmaceutical technology, in particular as excipients for galenic use. Provided is a method for either admixture of hydrophobins to galenic compositions or for treating the surface of pharmaceutical forms with a hydrophobin-containing solution to modify the pharmaceutical properties of the galenic form. In a preferred embodiment of the invention hydrophobins are used to improve the properties of a pharmaceutical composition, e.g. to act as a surfactant or to increase resistance to disintegration of the galenic forms to achieve a retarded drug release. The galenic form to be modified by the use of surface active proteins as excipients can be capsules, tablets, pills, microparticles, vesicles, and suppositories, although further galenic forms are envisioned. The surface active proteins used for the purpose of present invention can either be isolated from their respective natural source or prepared by recombinant techniques and expression in a suitable host.
    • 本发明涉及用于制药技术中的表面活性疏水蛋白的用途,特别是作为涂覆液使用的赋形剂。 提供了将疏水蛋白与盖仑组合物混合或用含疏水蛋白的溶液处理药物形式的表面以改变盖仑膜形式的药物性质的方法。 在本发明的优选实施方案中,疏水蛋白用于改善药物组合物的性质,例如, 作为表面活性剂或增加耐受霜冻形式的崩解以实现延缓药物释放。 通过使用表面活性蛋白质作为赋形剂来修饰的盖仑形式可以是胶囊,片剂,丸剂,微粒,囊泡和栓剂,尽管可以预见到更多的盖仑制剂形式。 用于本发明目的的表面活性蛋白质可以从其各自的天然来源分离或通过重组技术制备并在合适的宿主中表达。
    • 10. 发明授权
    • Chimeric surface active proteins
    • 嵌合表面活性蛋白
    • US08993743B2
    • 2015-03-31
    • US13579910
    • 2011-02-18
    • Guido MeurerEsther GaborAnke BachertJürgen Eck
    • Guido MeurerEsther GaborAnke BachertJürgen Eck
    • C07H21/04C07K14/37C12N15/62A61K9/28C09D189/00
    • C07K14/37A61K9/286A61K9/2873C09D189/00C12N15/62
    • The present invention relates to a nucleic acid molecule encoding a chimeric protein having the biochemical activity of a surface active protein, wherein said chimeric protein comprises: (a) an N-terminal portion of a first surface active protein, wherein the N-terminal portion is devoid of between 0 and 10 of the most N-terminal amino acids of the mature first surface active protein; and, C-terminally thereof, (b) a C-terminal portion of a second surface active protein, wherein the C-terminal portion is devoid of between 0 and 10 of the most C-terminal amino acids of the mature second surface active protein. The present invention further relates to a vector, a non-human host and a method for the production of a chimeric protein having the biochemical activity of a surface active protein. In addition, the present invention relates to a chimeric protein encoded by the nucleic acid molecule of the invention and a composition comprising the chimeric protein. The chimeric protein may only consist of the above mentioned core of (a) and (b), but may also be flanked by additional components of the core, i.e. (a) or (b) or by (an) additional complete core(s) (a) and (b). The present invention furthermore relates to a method of coating and/or impregnating a material, comprising contacting the material with the chimeric protein or the composition of the invention.
    • 本发明涉及编码具有表面活性蛋白的生化活性的嵌合蛋白的核酸分子,其中所述嵌合蛋白包含:(a)第一表面活性蛋白的N末端部分,其中所述N末端部分 没有成熟的第一表面活性蛋白的最多N末端氨基酸的0和10之间; 并且其C末端,(b)第二表面活性蛋白质的C末端部分,其中所述C末端部分缺少所述成熟第二表面活性蛋白质的最C末端氨基酸的0至10个 。 本发明还涉及载体,非人宿主和生产具有表面活性蛋白的生化活性的嵌合蛋白的方法。 此外,本发明涉及由本发明的核酸分子编码的嵌合蛋白质和包含该嵌合蛋白质的组合物。 嵌合蛋白质只能由上述(a)和(b)的核心组成,但也可以由核心的另外的组分,即(a)或(b)或另外一个完整的核心 )(a)和(b)。 本发明还涉及一种涂覆和/或浸渍材料的方法,包括使材料与本发明的嵌合蛋白或组合物接触。